The paragraph that I like the best is this one..........Management remains confident that these confirmatory trials will support the conclusions of the Phase II trials that ArTiMist can provide a viable alternative to the commonly accepted treatment of intravenous I quinine.
We know that phase II trials were fine and given that management will have some raw data there is confidence underlying this statement.
kippax
EMS Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held